Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.
复制标题
舒尼替尼作为多靶点酪氨酸激酶抑制剂 (TKI) 在实体癌中的临床反应：临床试验回顾
DOI：
10.2147/ott.s61388
复制
发表时间：
2014
影响因子：
4
通讯作者：
Chen S
中科院分区：
文献类型：
--
作者：
Kim S;Ding W;Zhang L;Tian W;Chen S
血管生成是癌症发生的一个完整过程，目前正在测试血管生成因子的分子抑制剂作为癌症的治疗方法。舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂，通过干细胞因子受体（Kit）和血小板衍生生长因子受体阻断活化。舒尼替尼已在多项II/III期试验中显示出对多种实体瘤的强效抗肿瘤活性，包括肾细胞癌、胃肠道间质瘤和神经内分泌肿瘤。最近，舒尼替尼已被用于治疗其他实体癌，如肺癌、胰腺癌、软骨肉瘤、食管癌、膀胱癌、神经胶质瘤和侵袭性纤维瘤病，并且在无进展生存期和总生存期方面也显示出潜在的疗效。在这篇综述中，我们研究了舒尼替尼作为分子靶向治疗在不同类型的实体癌患者中的疗效。
Angiogenesis is an integral process in carcinogenesis, and molecular inhibitors of angiogenic factors are currently being tested as treatments for cancer. Sunitinib is an oral multitargeted tyrosine-kinase inhibitor that blocks activation through the stem cell-factor receptor (Kit) and platelet-derived growth-factor receptor. Sunitinib has shown potent antitumor activity against several solid tumors, including renal cell carcinoma, gastrointestinal stromal tumors, and neuroendocrine tumors in several Phase II/III trials. Recently, sunitinib has been used to treat other solid cancers, such as lung cancer, pancreatic cancer, chondrosarcoma, esophageal cancer, bladder cancer, glioma, and aggressive fibromatosis, and also showed potential efficacy in progression-free survival and overall survival. In this review, we examine the efficacy of sunitinib as a molecular-targeted therapy in patients with different types of solid cancers.